Detalhe da pesquisa
1.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 390(2): 118-131, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197815
2.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
N Engl J Med
; 389(20): 1839-1850, 2023 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870973
3.
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 566(7745): E11-E12, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755741
4.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 554(7691): 189-194, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420467
5.
Decision-making as discovery: Vetting clinical research in a leading precision oncology service.
Sociol Health Illn
; 46(3): 495-513, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37796533
6.
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
Cancer
; 129(23): 3772-3782, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37769113
7.
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
N Engl J Med
; 383(9): 825-835, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32846061
8.
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(9): 813-824, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32846060
9.
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Lancet Oncol
; 23(10): 1261-1273, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108661
10.
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers.
Br J Cancer
; 126(6): 889-898, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34963703
11.
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
Br J Cancer
; 126(3): 514-520, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480094
12.
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers.
Oncologist
; 2022 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35536733
13.
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
Invest New Drugs
; 40(6): 1263-1273, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35947247
14.
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
BMC Cancer
; 22(1): 625, 2022 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35672677
15.
Testing methods to diagnose TRK fusion cancer - a plain language summary and patient perspective.
Future Oncol
; 18(38): 4141-4151, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36606522
16.
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer.
Future Oncol
; 18(28): 3133-3141, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950566
17.
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.
Oncologist
; 26(10): e1844-e1853, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34132450
18.
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Oncologist
; 26(1): 7-16, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32852072
19.
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
N Engl J Med
; 378(8): 731-739, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29466156
20.
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.
Future Oncol
; 17(7): 763-773, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33150799